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Background
The incidence of Kaposi Sarcoma (KS) is high in sub-
Saharan Africa. Data on KS among HIV-infected
patients receiving and not yet receiving antiretroviral
therapy (ART) are, however, scarce in Africa. Within
the framework of a large multi-cohort project, the Inter-
national epidemiologic Database to Evaluate AIDS
(IeDEA), we estimate the incidence and risk factors for
the development of KS in HIV-infected patients in
Southern Africa.
Methods
We analyzed prospectively collected data of HIV-
infected children and adults participating in IeDEA-SA.
We included all patients who were ART naive at start of
observation, regardless of cancer history, with at least 30
days follow up. Prevalent KS cases were also excluded.
Incidence rates and 95% confidence intervals (CI) were
calculated based on the Poisson distribution; risk factors
were estimated using crude and adjusted Cox propor-
tional hazard models. Hazard ratios (HR) with 95% CI
and medians with interquartile ranges (IQR) are
presented.
Results
We included 184,592 patients from 10 cohort studies in
Botswana, Mozambique, South Africa, Zambia and Zim-
babwe. The median age was 34 years (IQR 28–41), the
median CD4 cell count at first contact was 152 cells/µl
(IQR 75-252) and 146 cells/µl (IQR 74-226) at start of
ART. 61% of patients were female. During a total fol-
low-time of 391,852 person-years, 349 patients devel-
oped KS before starting ART, 585 developed KS after
starting ART and 183,658 remained KS-free. In patients
not receiving ART the KS incidence rate was 624 (95%
CI 562–692) per 100,000 person-years and in patients
receiving ART the KS incidence rate was 174 (95% CI
161-189) per 100,000 person-years, rate ratio for ART
versus no ART = 0.28 (95% CI 0.24 - 0.32). Univariate
a n dm u l t i v a r i a t ea n a l y s e ss h o w e dt h a tm e nw e r em o r e
likely than women to develop KS and that the incidence
rate for KS increased with increasing age and with
decreasing CD4 cell counts. These effects were more
pronounced in patients not receiving ART than in
patients receiving ART.
Conclusions
In Southern African countries with a high prevalence of
HHV-8 the risk of developing KS in HIV infected
patients receiving ART increases steeply with age and
immune-suppression. ART reduced the incidence of KS
substantially.
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